Stockscreener 앱 받기
2.69
1.89%
0.05
시간 외 거래:
2.62
-0.07
-2.60%
Sonoma Pharmaceuticals Inc 주식(SNOA)의 최신 뉴스
Sonoma Pharmaceuticals announces executive equity grants By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals announces executive equity grants - Investing.com India
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock - MSN
Sonoma Pharmaceuticals, Inc. Announces Two Singapore Approvals for Microcyn for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars - Marketscreener.com
Keloid Treatment Market Top PlayersNovartis AG, Sensus - openPR
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
SNOA stock touches 52-week low at $2.44 amid market challenges - Investing.com
SNOA stock touches 52-week low at $2.44 amid market challenges By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Market Fluctuati - GuruFocus.com
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges - Investing.com Canada
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices - AccessWire
Sonoma Pharmaceuticals (SNOA) Stock Declines Amid Market Activit - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) PE Ratio : At Loss (As of Nov. 30, 2024) - GuruFocus.com
SNOA (Sonoma Pharmaceuticals) Debt-to-Equity : 0.05 (As of Sep. 2024) - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) Growth Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Eye Care Product Lines - Trend Hunter
Alkermes (ALKS) Stock Surges Over 5% Amid Strong Financial Perfo - GuruFocus.com
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States - BioSpace
Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel - Marketscreener.com
Scar Treatment Market Detailed In New Research Report 2024 | - openPR
Sonoma Pharmaceuticals ends agreement with EMC Pharma - Investing.com
Merck (MRK) Stock Surges Amid Industry Layoff Trends - GuruFocus.com
Sonoma Pharmaceuticals ends agreement with EMC Pharma By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in - PharmiWeb.com
Amarin (AMRN) Stock Surges Amid Mixed Industry Performance - GuruFocus.com
Sonoma Pharmaceuticals Announces Relaunch of - One News Page
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.86% - MSN
Animal Wound Care Market to Exhibit a Remarkable CAGR of 7.9% - openPR
AMGN Stock Drops 5% Amid Industry Decline and Earnings Report - GuruFocus.com
Siga Technologies (SIGA) Sees Significant Stock Decline Amidst P - GuruFocus.com
Sonoma Pharmaceuticals gains FDA clearance for hydrogel By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Sonoma Pharmaceuticals gains FDA clearance for hydrogel - Investing.com India
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel - AccessWire
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Sonoma Pharmaceuticals Inc. (SNOA) Quarterly 10-Q Report - Quartz
Sonoma Pharmaceuticals Inc (SNOA) Quarterly 10-Q Report - Quartzy
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results - AccessWire
0.50%
2.86%
자본화:
|
볼륨(24시간):